Development of the Commercial Manufacturing Process for Ipatasertib

Development of the Commercial Manufacturing Process for Ipatasertib

Ipatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the com...

Full description

Bibliographic Details
Main Authors: Stephan Bachmann, Hans Iding, Christian Lautz, Isabelle Thomé-Pfeiffer, Caroline Maierhofer, Régis Mondière, Christoph Strasser, Thomas Bär, André Aebi, Andre Schuster, Philipp Schmidt
Format: Article
Language:deu
Published: Swiss Chemical Society 2021-08-01
Series:CHIMIA
Subjects:
biocatalysis
catalysis
drug development
enzyme
metal catalysis
green chemistry
Description
Summary:Ipatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.
ISSN:0009-4293
2673-2424

Similar Items